Cover Image

Neurocognitive effects of agomelatine treatment in schizophrenia patients suffering from comorbid depression: results from the AGOPSYCH study

AbstractBackgroundCognitive impairment in schizophrenia is highly disabling and remains one of the major therapeutic challenges. Agomelatine (AGO), an agonist at melatonergic MT1/MT2 receptors and antagonist at 5-HT2C receptors, increases dopamine and norepinephrine in the prefrontal cortex and may

Saved in:
Bibliographic Details
Main Authors: Englisch, Susanne Angelika (Author) , Meyer-Lindenberg, Andreas (Author) , Zink, Mathias (Author)
Format: Article (Journal)
Language:English
Published: August 2018
In: Journal of clinical psychopharmacology
Year: 2018, Volume: 38, Issue: 4, Pages: 357-361
ISSN:1533-712X
DOI:10.1097/JCP.0000000000000909
Online Access:Verlag, Volltext: https://doi.org/10.1097/JCP.0000000000000909
Verlag: insights.ovid.com
Get full text
Author Notes:Susanne Englisch, Hanna Jung, Sarah Eisenacher, Antje Lewien, Anna Becker, Ulrike Nowak, Hanna Braun, Jascha Thiem, Andreas Meyer-Lindenberg and Mathias Zink
Description
Summary:AbstractBackgroundCognitive impairment in schizophrenia is highly disabling and remains one of the major therapeutic challenges. Agomelatine (AGO), an agonist at melatonergic MT1/MT2 receptors and antagonist at 5-HT2C receptors, increases dopamine and norepinephrine in the prefrontal cortex and may
Item Description:Gesehen am 30.01.2020
Physical Description:Online Resource
ISSN:1533-712X
DOI:10.1097/JCP.0000000000000909

Similar Items